S100A16

Summary

S100A16 (S100 calcium binding protein A16, HGNC:20441) is a protein-coding gene on chromosome 1q21.3, encoding Protein S100-A16 (Q96FQ6). Calcium-binding protein.

Enables calcium ion binding activity and protein homodimerization activity. Predicted to act upstream of or within response to calcium ion. Located in several cellular components, including cytosol; extracellular space; and nucleolus.

Source: NCBI Gene 140576 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 17 total
• MANE Select transcript: NM_080388

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20441
Approved symbol	S100A16
Name	S100 calcium binding protein A16
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	S100F, DT1P1A7, MGC17528
Ensembl gene	ENSG00000188643
Ensembl biotype	protein_coding
OMIM	617437
Entrez	140576

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 27 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000368703, ENST00000368704, ENST00000368705, ENST00000368706, ENST00000474991, ENST00000852960, ENST00000852961, ENST00000852962, ENST00000852963, ENST00000852964, ENST00000852965, ENST00000852966, ENST00000852967, ENST00000852968, ENST00000852969, ENST00000852970, ENST00000852971, ENST00000852972, ENST00000852973, ENST00000852974, ENST00000852975, ENST00000852976, ENST00000913004, ENST00000913005, ENST00000913006, ENST00000970156, ENST00000970157, ENST00000970158

RefSeq mRNA: 3 — MANE Select: NM_080388 NM_001317007, NM_001317008, NM_080388

CCDS: CCDS1045

Canonical transcript exons

ENST00000368706 — 3 exons

Exon	Start	End
ENSE00001447809	153606886	153607692
ENSE00001951512	153612952	153613137
ENSE00003645863	153607999	153608177

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 99.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 107.5889 / max 933.4106, expressed in 1451 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14681	45.2564	1276
14683	21.5148	1222
14674	11.2892	1044
14675	10.7711	1111
14676	6.7975	1075
14682	4.1698	1054
14684	3.1045	675
14673	1.0244	410
14679	0.9874	521
14671	0.7586	492

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.91	gold quality
pharyngeal mucosa	UBERON:0000355	99.78	gold quality
esophagus mucosa	UBERON:0002469	99.73	gold quality
ileal mucosa	UBERON:0000331	99.72	gold quality
upper arm skin	UBERON:0004263	99.68	gold quality
gingival epithelium	UBERON:0001949	99.66	gold quality
gingiva	UBERON:0001828	99.65	gold quality
oral cavity	UBERON:0000167	99.58	gold quality
esophagus squamous epithelium	UBERON:0006920	99.57	gold quality
nasal cavity epithelium	UBERON:0005384	99.45	gold quality
mammalian vulva	UBERON:0000997	99.39	gold quality
penis	UBERON:0000989	99.32	gold quality
skin of abdomen	UBERON:0001416	99.31	gold quality
body of tongue	UBERON:0011876	99.27	gold quality
skin of leg	UBERON:0001511	99.21	gold quality
zone of skin	UBERON:0000014	99.17	gold quality
mucosa of transverse colon	UBERON:0004991	99.10	gold quality
nipple	UBERON:0002030	98.95	gold quality
vagina	UBERON:0000996	98.83	gold quality
mouth mucosa	UBERON:0003729	98.63	gold quality
upper leg skin	UBERON:0004262	98.63	gold quality
tongue	UBERON:0001723	98.59	gold quality
minor salivary gland	UBERON:0001830	98.47	gold quality
pancreatic ductal cell	CL:0002079	98.25	gold quality
buccal mucosa cell	CL:0002336	98.12	gold quality
stromal cell of endometrium	CL:0002255	98.11	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.06	gold quality
kidney epithelium	UBERON:0004819	98.06	gold quality
colonic mucosa	UBERON:0000317	98.05	gold quality
upper lobe of left lung	UBERON:0008952	98.05	gold quality

Single-cell (SCXA)

Detected in 34 experiment(s), a significant marker in 30.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	3649.09
E-CURD-98	yes	1358.24
E-MTAB-7407	yes	1085.54
E-MTAB-8271	yes	1070.29
E-CURD-112	yes	883.10
E-MTAB-8530	yes	869.37
E-MTAB-9435	yes	611.34
E-ANND-5	yes	592.96
E-CURD-6	yes	551.97
E-MTAB-9801	yes	540.59
E-GEOD-76312	yes	476.94
E-GEOD-109979	yes	321.75
E-MTAB-8142	yes	136.82
E-MTAB-6701	yes	128.13
E-MTAB-10553	yes	57.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting S100A16, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-6083	99.47	68.73	2393
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-329-5P	99.27	68.11	1597
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-1295B-5P	99.03	67.50	810
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-6847-5P	97.93	66.74	1808

Literature-anchored findings (GeneRIF, showing 24)

• The presence of hydrophobic interactions stronger than for other S100 proteins, present in the closed form of S100A16 between the third and fourth helices, likely make the closed structure of the second EF-hand particularly stable. (PMID:21046186)
• S100A16 had a potential function to regulate some embryonic transcription factors to promote epithelial-mensenchymal transition in breast cancer cells which may be an important target site for the therapy of breast cancer. (PMID:25287362)
• Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion (PMID:25884418)
• These results indicate that S100 calcium binding protein A16 is a differentiation promoting protein and might function as a tumor suppressor in oral squamous cell carcinoma. (PMID:26353754)
• Data show that overexpression of S100 calcium binding protein A16 protein (S100A16) activated AKT protein and ERK signaling pathways. (PMID:27240591)
• Low S100A16 expression is associated with colorectal cancer. (PMID:28876468)
• Our results suggest that the subcellular localization of S100A16 and S100A16 mRNA expression levels is a promising prognostic marker for lung adenocarcinoma. (PMID:29320753)
• MANF showed not only transient but also long-lasting neuroprotective pro (PMID:30183374)
• Inhibition assays suggested these two signalling pathways participated in the S100A16-mediated proliferation and survival effects in B-cell ALL cell lines. (PMID:30916375)
• S100A16 might promote lipid synthesis in HepG2 cells through endoplasmic reticulum stress HSPA5/IRE1alpha-XBP1 pathway. (PMID:31008487)
• S100A16 could promote the proliferation, migration, and tumor angiogenesis of HeLa cells by regulating the phosphatidylinositol 3 kinase/protein kinase B signaling pathways. (PMID:31894756)
• Interaction of calcium binding protein S100A16 with myosin-9 promotes cytoskeleton reorganization in renal tubulointerstitial fibrosis. (PMID:32094322)
• S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway. (PMID:33355370)
• S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. (PMID:33359364)
• S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. (PMID:33389337)
• The interaction of S100A16 and GRP78 actives endoplasmic reticulum stress-mediated through the IRE1alpha/XBP1 pathway in renal tubulointerstitial fibrosis. (PMID:34645789)
• Downregulated Calcium-Binding Protein S100A16 and HSP27 in Placenta-Derived Multipotent Cells Induce Functional Astrocyte Differentiation. (PMID:35061207)
• Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway. (PMID:36176934)
• New progress with calcium-binding protein S100A16 in digestive system disease. (PMID:36718596)
• S100 Calcium Binding Protein A16 Promotes Cell Proliferation by triggering LATS1 ubiquitin degradation mediated by CUL4A ligase to inhibit Hippo pathway in Glioma development. (PMID:37151881)
• An Update on S100A16 in Human Cancer. (PMID:37509106)
• S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer. (PMID:38733818)
• Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer. (PMID:38924205)
• S100A16 stabilizes the ITGA3-mediated ECM-receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10. (PMID:39450567)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	icn	ENSDARG00000009978
danio_rerio	icn2	ENSDARG00000055514
mus_musculus	S100a16	ENSMUSG00000074457
rattus_norvegicus	S100a16	ENSRNOG00000012053

Paralogs (21): CRNN (ENSG00000143536), S100A8 (ENSG00000143546), S100A7 (ENSG00000143556), S100B (ENSG00000160307), S100A1 (ENSG00000160678), S100A11 (ENSG00000163191), S100A9 (ENSG00000163220), S100A12 (ENSG00000163221), S100P (ENSG00000163993), S100G (ENSG00000169906), S100Z (ENSG00000171643), S100A7A (ENSG00000184330), S100A3 (ENSG00000188015), SNTN (ENSG00000188817), S100A13 (ENSG00000189171), S100A14 (ENSG00000189334), S100A4 (ENSG00000196154), S100A5 (ENSG00000196420), S100A2 (ENSG00000196754), S100A10 (ENSG00000197747), S100A6 (ENSG00000197956)

Protein

Protein identifiers

Protein S100-A16 — Q96FQ6 (reviewed: Q96FQ6)

Alternative names: Aging-associated gene 13 protein, Protein S100-F, S100 calcium-binding protein A16

All UniProt accessions (1): Q96FQ6

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-binding protein. Binds one calcium ion per monomer. Can promote differentiation of adipocytes (in vitro). Overexpression in preadipocytes increases their proliferation, enhances adipogenesis and reduces insulin-stimulated glucose uptake.

Subunit / interactions. Homodimer. Interacts with TP53.

Subcellular location. Nucleus. Nucleolus. Cytoplasm.

Tissue specificity. Ubiquitous. Highly expressed in esophagus, adipose tissues and colon. Expressed at lower level in lung, brain, pancreas and skeletal muscle. Expression is up-regulated in tumors of bladder, lung, thyroid gland, pancreas and ovary. Expressed in astrocytes.

Domain organisation. S100A16 proteins, but not other S100 proteins, have only one functional Ca(2+) binding site per monomer. Upon Ca(2+) binding, undergoes conformational changes leading to the exposure of hydrophobic patches which could be implicated in the Ca(2+) -dependent nuclear export. Binds Zn(2+). Ca(2+) and Zn(2+) do not bind to the same site. Does not bind Cu(2+).

Similarity. Belongs to the S-100 family.

RefSeq proteins (3): NP_001303936, NP_001303937, NP_525127* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001751	S100/CaBP7/8-like_CS	Conserved_site
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR013787	S100_Ca-bd_sub	Domain
IPR018247	EF_Hand_1_Ca_BS	Binding_site

Pfam: PF01023

UniProt features (18 total): helix 7, binding site 5, domain 2, turn 2, chain 1, strand 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
3NXA	X-RAY DIFFRACTION	2.1
2L50	SOLUTION NMR
2L51	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96FQ6-F1	81.56	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 67; 69; 71; 73; 78

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 139 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GGGTGGRR_PAX4_03, GOBP_RESPONSE_TO_METAL_ION, RICKMAN_METASTASIS_DN, P300_01, GOBP_RESPONSE_TO_CALCIUM_ION, LEIN_OLIGODENDROCYTE_MARKERS, chr1q21, GOCC_NUCLEOLUS, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_PROTEIN_HOMODIMERIZATION_ACTIVITY, GOMF_CALCIUM_DEPENDENT_PROTEIN_BINDING, EVI1_02, AP2ALPHA_01, HNF4ALPHA_Q6

GO Biological Process (1): response to calcium ion (GO:0051592)

GO Molecular Function (7): RNA binding (GO:0003723), calcium ion binding (GO:0005509), protein homodimerization activity (GO:0042803), calcium-dependent protein binding (GO:0048306), protein binding (GO:0005515), identical protein binding (GO:0042802), metal ion binding (GO:0046872)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleolus (GO:0005730), cytosol (GO:0005829), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein binding	2
cytoplasm	2
response to metal ion	1
nucleic acid binding	1
metal ion binding	1
identical protein binding	1
protein dimerization activity	1
calcium ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1895 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
S100A16	S100A14	Q9HCY8	802
S100A16	S100A3	P33764	785
S100A16	S100A5	P33763	762
S100A16	S100A6	P06703	668
S100A16	S100A7	P31151	654
S100A16	S100A11	P31949	615
S100A16	S100A10	P08206	594
S100A16	S100G	P29377	588
S100A16	S100A7A	Q86SG5	519
S100A16	S100A12	P80511	508
S100A16	S100A2	P29034	506
S100A16	S100A7L2	Q5SY68	448
S100A16	S100A4	P26447	442
S100A16	HSPA5	P11021	436
S100A16	ANXA2	P07355	430
S100A16	A0A087WTN9	A0A087WTN9	430

IntAct

48 interactions, top by confidence:

A	B	Type	Score
S100A14	S100A16	psi-mi:“MI:0915”(physical association)	0.780
S100A16	S100A14	psi-mi:“MI:0915”(physical association)	0.780
TBC1D22B	A2ML1	psi-mi:“MI:0914”(association)	0.530
GMCL1	A2ML1	psi-mi:“MI:0914”(association)	0.530
ZIC1	CTSV	psi-mi:“MI:0914”(association)	0.530
DPPA4	ALOX12B	psi-mi:“MI:0914”(association)	0.530
ERBB2	NDUFA4	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
S100A16	TP53	psi-mi:“MI:0407”(direct interaction)	0.440
	ESYT2	psi-mi:“MI:0914”(association)	0.350
E5	ESYT2	psi-mi:“MI:0914”(association)	0.350
ZIC1	IMPA2	psi-mi:“MI:0914”(association)	0.350
UBAC2	HAL	psi-mi:“MI:0914”(association)	0.350
ENG	IGKV2-28	psi-mi:“MI:0914”(association)	0.350
HTRA4	PSMD12	psi-mi:“MI:0914”(association)	0.350
GABARAPL1		psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
SRRT	A2ML1	psi-mi:“MI:0914”(association)	0.350
PI4KAP1	A2ML1	psi-mi:“MI:0914”(association)	0.350
ST6GALNAC6	A2ML1	psi-mi:“MI:0914”(association)	0.350
RIPPLY3	A2ML1	psi-mi:“MI:0914”(association)	0.350
PRXL2A	A2ML1	psi-mi:“MI:0914”(association)	0.350

BioGRID (83): S100A16 (Two-hybrid), S100A16 (Affinity Capture-RNA), S100A16 (Affinity Capture-RNA), S100A16 (Affinity Capture-MS), S100A16 (Two-hybrid), S100A16 (Affinity Capture-MS), S100A16 (Affinity Capture-MS), S100A16 (Affinity Capture-MS), S100A16 (Affinity Capture-MS), S100A16 (Two-hybrid), S100A16 (Biochemical Activity), S100A16 (Affinity Capture-MS), S100A16 (Affinity Capture-MS), S100A14 (Two-hybrid), S100A16 (Affinity Capture-MS)

ESM2 similar proteins: O77691, O77791, P02638, P02639, P04271, P04354, P04467, P04631, P05937, P05942, P05964, P06702, P06703, P07091, P07171, P10462, P12658, P14069, P23297, P24479, P25815, P26447, P27004, P28318, P29034, P30801, P31151, P35466, P35467, P50114, P56565, P79105, P79880, P80310, P80511, P97352, Q0VCM0, Q14ST5, Q28050, Q2EN75

Diamond homologs: A7K6Y9, O77691, O77791, P02632, P02633, P02634, P02638, P02639, P04271, P04631, P05942, P05964, P06702, P06703, P07091, P10462, P14069, P20930, P23297, P24480, P25815, P26447, P27003, P28318, P28783, P29034, P29377, P30801, P33763, P33764, P35466, P35467, P50114, P50116, P50117, P56565, P62818, P62819, P63083, P63084

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

17 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	10
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

384 predictions. Top by Δscore:

Variant	Effect	Δscore
1:153607689:TGTC:T	acceptor_gain	1.0000
1:153607690:GTC:G	acceptor_gain	1.0000
1:153607691:TC:T	acceptor_gain	1.0000
1:153607692:CC:C	acceptor_gain	1.0000
1:153607693:C:CC	acceptor_gain	1.0000
1:153607993:CCTTA:C	donor_loss	1.0000
1:153607994:CTTA:C	donor_loss	1.0000
1:153607995:TTA:T	donor_loss	1.0000
1:153607996:TAC:T	donor_loss	1.0000
1:153607997:A:AC	donor_gain	1.0000
1:153607997:A:C	donor_loss	1.0000
1:153607997:AC:A	donor_gain	1.0000
1:153607998:C:CG	donor_gain	1.0000
1:153607998:CC:C	donor_gain	1.0000
1:153607998:CCG:C	donor_gain	1.0000
1:153607998:CCGA:C	donor_gain	1.0000
1:153608174:GGGC:G	acceptor_gain	1.0000
1:153608178:C:CC	acceptor_gain	1.0000
1:153608183:C:CT	acceptor_gain	1.0000
1:153608186:C:CT	acceptor_gain	1.0000
1:153608186:C:T	acceptor_gain	1.0000
1:153608187:A:T	acceptor_gain	1.0000
1:153607688:GTGTC:G	acceptor_gain	0.9900
1:153607693:C:T	acceptor_gain	0.9900
1:153608173:GGGGC:G	acceptor_gain	0.9900
1:153608175:GGC:G	acceptor_gain	0.9900
1:153608176:GC:G	acceptor_gain	0.9900
1:153608177:CC:C	acceptor_gain	0.9900
1:153609229:AGGGG:A	donor_gain	0.9900
1:153608688:C:A	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000210330 (1:153609290 C>G), RS1000417429 (1:153611234 C>A,G), RS1000536647 (1:153610208 G>A,T), RS1000585430 (1:153609084 A>G), RS1000679863 (1:153610270 T>C), RS1000949656 (1:153610449 T>C), RS1001330521 (1:153609479 C>T), RS1001836786 (1:153615047 C>A,T), RS1001884878 (1:153611038 C>G,T), RS1002292710 (1:153611136 A>C,T), RS1002418026 (1:153608762 A>G), RS1003213451 (1:153607593 C>A,G,T), RS1003233935 (1:153612109 AACAC>A,AAC,AACACAC), RS1003334724 (1:153612272 G>C), RS1003580250 (1:153607039 G>A)

Disease associations

OMIM: gene MIM:617437 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	5
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	3
bisphenol A	affects expression, decreases expression	2
Estradiol	affects expression, decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Valproic Acid	decreases expression, increases expression	2
Cadmium Chloride	increases expression, decreases reaction, increases abundance, increases palmitoylation	2
pirinixic acid	affects binding, decreases expression, increases activity	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
lewisite	increases expression	1
2,3-dimethoxy-1,4-naphthoquinone	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
chloropicrin	decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
ICG 001	decreases expression	1
bisphenol S	increases expression	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Sunitinib	decreases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Atrazine	increases expression	1
Cadmium	increases abundance, increases palmitoylation, decreases reaction	1
Carbamazepine	affects expression	1
Diethylhexyl Phthalate	increases expression	1
Diethylnitrosamine	increases expression	1
Doxorubicin	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2EG	Abcam HeLa S100A16 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.